IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...

Allergan plcAGN announced that it has launched Juvéderm Voluma XC in the U.S. The product is a new addition to the Juvéderm range of fillers for lip augmentation and for correcting perioral rhytids, ...

DUBLIN, Oct. 3, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today the launch of a new JUVÉDERM ® advertising campaign created to empower the next generation of consumers to "JUVÉDERM ® IT.

"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...

Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...

Please provide your email address to receive an email when new articles are posted on . “Because there are no permanent adverse reactions or deforming reactions, I think the safety is assured,” Karen ...